AEON Biopharma (AEON) Return on Capital Employed (2021 - 2026)
AEON Biopharma (AEON) posted Return on Capital Employed of 5121.6% for Q4 2025, down 949.46% sequentially from 488.02% in Q3 2025, and down 443149.0% YoY from N/an in Q4 2024.
AEON Biopharma (AEON) Return on Capital Employed (2021 - 2026) Analysis & Trends
AEON Biopharma has reported Return on Capital Employed for 5 years, with the latest figure at 5121.6% in Q4 2025.
- Quarterly Return on Capital Employed fell 443149.0% year-over-year to 5121.6% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 5121.6% (down 443149.0% YoY) and the FY2025 annual result came in at 502.87%, up 130004.0% from the prior year.
- Return on Capital Employed slipped to 5121.6% in Q4 2025 per AEON's latest filing, from 488.02% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 3611.68% in Q2 2024 and troughed at 86533.33% in Q1 2025.
- A 5-year average of 5576.27% and a median of 175.57% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed jumped 945417 bps in 2024, then slumped 9002638 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 0.7% in 2021, then plunged by 5880 bps to 41.91% in 2022, then sank by 13969 bps to 5895.92% in 2023, then soared by 88 bps to 690.11% in 2024, then sank by 642 bps to 5121.6% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 5121.6%, 488.02%, and 309.23% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | AEON Biopharma | 10.06 Mn | 6.62 Mn | - | 1,136.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1,136.34% |
| Dec 31, 2025 | -5,121.60% |
| Sep 30, 2025 | -488.02% |
| Jun 30, 2025 | -309.23% |
| Mar 31, 2025 | -86,533.33% |
| Dec 31, 2024 | -690.11% |
| Sep 30, 2024 | 3,558.26% |
| Jun 30, 2024 | 3,611.68% |
| Mar 31, 2024 | 3,493.04% |
| Sep 30, 2023 | -5,895.92% |
| Jun 30, 2023 | -424.53% |
| Mar 31, 2023 | -372.14% |
| Dec 31, 2022 | -41.91% |
| Sep 30, 2022 | -4.21% |
| Jun 30, 2022 | -0.78% |
| Mar 31, 2022 | -0.77% |
| Dec 31, 2021 | -0.70% |